ClinicalTrials.gg

Program

HRS-5817

A development code. Also written as “HRS-5817 Injection”.

Its studies are mostly in Obesity, led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Apr 11, 20252 company-led studies, 2 open or runningNext primary completion: Jan 30, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine22 open or runningphase 1since Apr 11, 2025Apr 11, 2025Jan 30, 2027early phase 1 · NCT07238647
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-5817, phase 1, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 11, 2025First study: phase 1 study in ObesityFirst studyNCT06934408 · 92 planned · China
  2. Nov 16, 2025Early phase 1 study in ObesityNCT07238647 · 40 enrolled · Australia

Ahead

  1. Jan 30, 2027Primary completion: early phase 1 study in ObesityNCT07238647
  2. Apr 2027Primary completion: phase 1 study in ObesityNCT06934408

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07238647Obesity · AustraliaEarly 1Active, not recruitingJan 30, 202740
NCT06934408Obesity · China1RecruitingApr 202792

How it is read

Names in the registry

  • “HRS-5817”, 4 entries
  • “HRS-5817 Injection”, 1 entry

Codes read as this program: HRS5817.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.